Systemic Lupus Erythematosus Market to Advance Upto Whopping USD 10 Billion by 2030 | DelveInsight

14 Jun 2022
www.prnewswire.com
AntibodyBiosimilarCollaborate
SystemicSystemic Lupus Erythematosus market size increment is a direct consequence of expected entry of promising emerging therapies, increasing awareness of the disease, and recent advancements in research and development in the 7MM
LAS VEGAS, June 14, 2022 /PRNewswire/ -- DelveInsight's
Systemic Lupus Erythematosus Market Insights report proffers a detailed comprehension of the Systemic Lupus Erythematosus market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Systemic Lupus Erythematosus market size from 2018 to 2030 segmented into the 7MM (the USA, EU5 ( Germany, France, Italy, Spain and the UK), and Japan).
Some of the salient features from the
Report:
DelveInsight analysts suggested that the Systemic Lupus Erythematosus market size in the
7MM was valued at
USD 1,462 Million in 2020 and is expected to increase drastically owing to the launches of several potential emerging therapies during the study period (2018-2030).
Key pharmaceutical Systemic Lupus Erythematosus companies such as
The Systemic Lupus Erythematosus emerging therapies that are expected to launch in the forecast period include
As per DelveInsight analysis, the United States accounted for the largest Systemic Lupus Erythematosus market size that was valued at
USD 1,181 million in 2020, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
The current Systemic Lupus Erythematosus therapeutic landscape in the 7MM is driven by current treatment practices and the expected launch of emerging therapies.
For further information on the market impact by therapies, download the Systemic Lupus Erythematosus sample @
Systemic Lupus Erythematosus Therapeutic Scenario
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. Genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. The pathogenesis of Systemic Lupus Erythematosus is complex, and the understanding of SLE pathogenesis is constantly evolving. A break in the tolerance in genetically susceptible individuals, on exposure to environmental factors, leads to the activation of autoimmunity.
Systemic Lupus Erythematosus Epidemiology Segmentation
As per the assessment of DelveInsight, the
total diagnosed prevalent Systemic Lupus Erythematosus population in the
7MM was found to be
651,965 in 2020 which is expected to increase during the study period.
As per DelveInsight's estimates, the
United States accounted for
351,176 Systemic Lupus Erythematosus prevalent cases.
The
Systemic Lupus Erythematosus Market report offers epidemiological analysis for the study period 2018-2030 in the 7MM segmented into
Total Diagnosed Prevalent Population of Systemic Lupus Erythematosus
Gender-specific Diagnosed Prevalent Population of Systemic Lupus Erythematosus
Age-specific Diagnosed Prevalent Population of Systemic Lupus Erythematosus
Severity-specific Diagnosed Prevalent Population of Systemic Lupus Erythematosus
Keen to learn how Systemic Lupus Erythematosus Epidemiological Trends are going to appear in 2030 for the 7 MM, Download @
Systemic Lupus Erythematosus Epidemiological Insights
There is no complete cure for Systemic Lupus Erythematosus currently, but there are many treatments available to help particular symptoms. Systemic Lupus Erythematosus involves a wide range of clinical features that encompasses vascular, immune, and fibrotic manifestations along with the involvement of many organs. Systemic Lupus Erythematosus treatment includes
NSAIDs and
antimalarial agents, which are the first-line therapies for mild Systemic Lupus Erythematosus. In addition,
glucocorticoids and
cytotoxic or immunosuppressive agents—such as
methotrexate —are used for Systemic Lupus Erythematosus treatment with organ involvement. The current Systemic Lupus Erythematosus market possesses two approved products,
The dynamics of the Systemic Lupus Erythematosus market is anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. It includes several  Systemic Lupus Erythematosus pipeline therapies such as
Lupuzor (also known as IPP-201101), being developed by
ImmuPharma, is a 21-mer linear peptide fragment analog. ImmuPharma has completed the Phase III clinical trial for the treatment of SLE. Lupuzor demonstrated a superior response rate over placebo (61.5% vs 47.3%). ImmuPharma and
Avion Pharmaceuticals signed exclusive license and development agreement for Lupuzor to fund a new
'optimized' international Phase III trial which is expected to start by 2022. Avion Pharmaceuticals has the exclusive rights for the commercialization of Lupuzor in the US. ImmuPharma retains all the rights to commercialize Lupuzor outside the US. Apart from this,
Biogen is developing,
BIIB059, is an investigational humanized monoclonal antibody that specifically recognizes and binds to blood DC antigen 2 (BDCA2), a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. Biogen is conducting
Phase III clinical trials for the treatment of patients receiving Active SLE receiving background nonbiologic lupus standard of care.
In addition,
Dapirolizumab pegol is being developed by
UCB Pharma in partnership with
Biogen. It is an investigational humanized anti-CD40L antibody fragment that acts by preventing the interaction between CD40L on T-cells with CD40 on antigen-presenting cells through interactions with its receptor-CD40. The drug failed to meet its primary endpoint in the Phase II trial. However, the company continued the development of dapirolizumab pegol. The product is currently being developed jointly by UCB and Biogen to treat SLE in a Phase III trial. The topline results are expected in the first-half of 2024.
Discover more about therapy set to grab substantial Systemic Lupus Erythematosus share @
Systemic Lupus Erythematosus Pipeline Therapies and Key Companies
Itolizumab: Equillium/Biocon Limited
ABBV-599: AbbVie
Gazyva/Gazyvaro (Obinutuzumab): Hoffman-La-Roche
Lupuzor: ImmuPharma
To know about more pipeline therapies covered in the report, visit @
Systemic Lupus Erythematosus Pipeline Analysis, Clinical Trials, and Emerging Therapies
The expected launch of
potential SLE therapies is the main factor responsible for an increase in the Systemic Lupus Erythematosus market size in the coming years, assisted by an
increase in the diagnosed Systemic Lupus Erythematosus prevalent population. Also, owing to the
positive outcomes of the several products during the developmental stage by
many key players, and
improvement in the research and development activities for efficient treatment options to be made available in the market will directly boost the Systemic Lupus Erythematosus market. The
increased awareness of the disease is also considered an aspect driving the Systemic Lupus Erythematosus market growth.
On the other hand, factors such as a
high annual cost and the
hit and trial approach of researchers serve as setbacks for the Systemic Lupus Erythematosus market growth. The
high failure rate of emerging drugs makes entering the SLE market challenging for the pharmaceutical key players. Also,
several obstacles experienced in the Systemic Lupus Erythematosus pipeline,
undiagnosed and unreported cases might also play as obstructions in the Systemic Lupus Erythematosus market in the future.
Know which therapy is expected to score the touchdown first @
Systemic Lupus Erythematosus Market Landscape and Forecast
Scope of the
Study Period: 2018-30
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and emerging therapies
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs
KOL's views
Analyst's views
Systemic Lupus Erythematosus Access and Reimbursement
Request for a Webex demo of the report
@
Table of Contents
Get in touch with our Business executive  @
Systemic Lupus Erythematosus Regulatory and Patent Analysis
Related Reports
DelveInsight's
"Cutaneous Lupus Erythematosus - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology, market drivers, market barriers and key companies included like
DelveInsight's
'Cervical Cancer –Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology, current treatment practices, emerging drugs like Cemiplimab, Durvalumab, Tisotumab vedotin, and key companies involved like
Genentech/Roche, Iovance Biotherapeutics, Advaxis, Agenus, Akeso Biopharma, Altor BioScience, Amgen/Allergan, AstraZeneca, Avastin Biosimilars, and others
Intratumoral Cancer Therapies Market
DelveInsight's
'Intratumoral Cancer Therapies - Market Insights, Epidemiology and Market Forecast—2032' report delivers an in-depth understanding of the Intratumoral Cancer Therapies, market drivers, market barriers, unmet medical needs, and key companies involved like
DelveInsight's
"Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Prostate cancer, emerging drugs, and key companies involved like
CAR-T Pipeline Insights
DelveInsight's,
"CAR-T – Pipeline Insights, 2022," report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including,
DelveInsight's,
"Acute Myeloid Leukemia (AML) - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including
Other Trending Reports
Hyperlipidemia Market
Plaque Modification Devices Market
Chronic smell and flavor loss Market
Metastatic Castration Resistant Prostate cancer Market
Sarcopenia Market
Adalimumab Biosimilars Insight, 2022
Medical Marijuana Market
Browse Through Our Blog Posts
How the Leading Companies are Countering the Rising Prevalence?
Aurinia's Lupkynis for Lupus
To Gain Rich Insights Explore
About
DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect With Us at LinkedIn
| Facebook | Twitter
Contact Us
[email protected]
+1(918)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.